Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance

Citius Pharmaceuticals IncTrade
iShares Broad USD Investment Grade Corporate BondTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while iShares Broad USD Investment Grade Corporate Bond trades at $50.21. The key difference: Citius Pharmaceuticals Inc is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.

CTXRUSIG
Market Cap
$18.73M
Sector
HealthFixed Income
52-Week High
$1.82$52.69
52-Week Low
$0.48$50.18
Enterprise Value
$14.95M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.

The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.

iShares Broad USD Investment Grade Corporate Bond

USIG trades at $50.40 with minimal daily movement (+0.16%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators remain neutral. The company maintains consistent dividend distributions, with recent payouts of $0.20-$0.21 per share. Recent news includes AM Best affirming credit ratings for subsidiaries following a transaction with Tiptree Inc.

Investment outlook remains cautious given bearish technical signals and limited fundamental data availability. The steady dividend history provides income appeal, but investors face uncertainty from incomplete financial metrics. Key risks include potential volatility from institutional positioning changes and transaction integration challenges with Tiptree.

Returns comparison

Trailing returns across standard periods

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About iShares Broad USD Investment Grade Corporate Bond

USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.

Read more on USIG